BioMarin Pharmaceutical(US:BMRN)2025-02-19 22:15Financial Performance Highlights - Total Revenues for Q4 2024 reached $747 million, a 16% increase compared to Q4 2023[11] - Full Year 2024 Total Revenues amounted to $285 billion, reflecting an 18% growth year-over-year[11] - VOXZOGO Revenues for Q4 2024 were $208 million, a 42% increase[12] - Enzyme Therapies Revenues for Q4 2024 totaled $488 million, a 9% increase[12] - GAAP Operating Margin for Q4 2024 was 216%, a 174 percentage points increase[12] - Non-GAAP Operating Margin for Q4 2024 was 311%, a 139 percentage points increase[12] - GAAP Diluted Earnings per Share (EPS) for Q4 2024 was $064, a 482% increase[12] - Non-GAAP Diluted EPS for Q4 2024 was $092, an 88% increase[12] Full Year Guidance - The company anticipates full-year 2025 Total Revenues to be in the range of $31 billion to $32 billion[19] - The company projects full-year 2025 Non-GAAP Operating Margin to be between 32% and 33%[19] - The company expects full-year 2025 Non-GAAP Diluted EPS to be in the range of $420 to $440[19]